TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“ Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected social anxiety disorder (“SAD”) and generalized anxiety disorder (“GAD”) as the initial target indications for its proprietary psychedelic molecule CYB004. “People struggle with many different mental…


Previous articleWhole-Body Effects of Psychedelics – Part 1
Next articleEntheon Biomedical Corp. Announces Agreement to Acquire Lobo Genetics Inc.